Skip to main content

Mutual Fund Review: Reliance Pharma

Investors looking to take a plunge in pharma space can consider Reliance Pharma given its diversified portfolio & healthy performance

 

RECKONED as a laggard till one-andhalf-year ago, the pharmaceuticals sector is now one of the front line stocks on the bourses. Over the past one year, pharmaceutical funds has rewarded investors with an average of about 88% returns, emerging as a top performer amongst all other sectoral or theme funds.


   And within the pharmaceutical funds category, Reliance Pharma has emerged as one of the top performers, consistently over a period of time. Launched in May 2004, the fund is in fact the last entrant in the category that comprises just about four similar funds — one each from UTI, Franklin Templeton and SBI Magnum.

PERFORMANCE:

Benchmarked to BSE Healthcare (HC) index, Reliance Pharma has consistently beaten its benchmark since the time of its launch – except for the year 2008 when it marginally underperformed BSE HC.


   Tracking its historic performance, the fund returned about 29% in 2005 even as BSE HC returned just about 1.8% in that year. And though the pharmaceutical sector was an underperformer in the year 2007 — the most bullish years of the decade, Reliance Pharma's relatively aggressive investment tactics helped it clock about 50% gains in that year against BSE HC's 16.5% then. The average returns by the category of pharmaceutical funds had stood at about 17% that year.


   In 2008, however, the decline of about 34% in the net asset value (NAV) of Reliance Pharma turned out to be sharper than that of BSE HC, which declined by about 33% that year. Those invested in the defensive pharmaceutical space may not have clocked in extremely handsome gains in 2007. But then they were equally well-off in the meltdown year which saw the major indices and the diversified equity schemes decline by over 50%. And given the rally in the pharmaceutical space last year (2009), those invested in the pharmaceutical space, especially in Reliance Pharma, have had ample reasons to rejoice.


   Even as BSE HC returned about 69% last year, the returns of Reliance Pharma soared by more than 118% beating even the Sensex and the Nifty returns of about 81% and 76%, respectively. Continuing its winning streak in the current calendar year, Reliance Pharma has returned about 11% since January this year against BSE HC's 5% returns during this period.


   The Sensex and the Nifty, given their extremely low weightages of about 1.3% and 2.4%, respectively in the pharmaceutical sector, have in fact generated negative returns of about 6% each till date in the current calendar year.

PORTFOLIO:

Unlike most other funds from the Reliance basket, which have preferences for high cash, especially in market volatilities, Reliance Pharma has sailed through the market tides with bare minimum levels of cash. The fund has held an average of just about 5.4% cash in the portfolio for over three years now. As far as its stock-holdings are concerned, currently its assets under management (AUM) worth Rs 360 crore is well diversified to about 18 stocks with exposure per stock restricted to about 8-9%. However, its bias to invest in the mid and small-cap space makes it relatively aggressive player in the pharmaceutical space.


   As this fund continues to hold many of its stocks for over three years now, it has made handsome gains on these holdings given the rally in the pharmaceutical space in the past year and a half. These include stocks like Aurobindo Pharma, Aventis Pharma, Divi's Labs and Sun Pharma.


   However, it is Zydus Wellness, which can be called the pick of the year for fund. Since the time Reliance Pharma has invested into this stock in April 2009, the stock has jumped by more than 500% till date. Its investment in Zydus Wellness currently account for nearly 6% of its AUM. As such, if one were to analyse the profitability quotient of Reliance Pharma's current portfolio, 100% of its equity holdings are currently in the profit zone.

OUR VIEW:

The popular maxim, patience pays, definitely holds true for the pharma investors, which has seen a dramatic turnaround in the past one-anda-half years. However, whether this rally in the pharma space continue in future is anyone's guess! As such, restricting ones investment to just a single sector calls for a great deal of caution and a high-risk appetite. And this risk appetite needs to be enhanced further in case of Reliance Pharma, given its high exposure to the small and mid-cap companies, which increases its beta as well as the risk quotient. But, given its well-diversified portfolio and healthy performance record, those willing to take a plunge in the pharma space can consider this fund.

 


Popular posts from this blog

ULIP Review: ProGrowth Super II

  If you are interested in a death cover that's just big enough, HDFC SL ProGrowth Super II is something worth a try. The beauty is it has something for everybody — you name the risk profile, the category is right up there. But do a SWOT analysis of the basket, and the gloss fades     HDFC SL ProGrowth Super II is a type-II unit-linked insurance plan ( ULIP ). Launched in September 2010, this is a small ticket-size scheme with multiple rider options and adequate death cover. It offers five investment options (funds) — one in each category of large-cap equity, mid-cap equity, balanced, debt and money market fund. COST STRUCTURE: ProGrowth Super II is reasonably priced, with the premium allocation charge lower than most others in the category. However, the scheme's mortality charge is almost 60% that of LIC mortality table for those investing early in life. This charge reduces with age. BENEFITS: Investors can choose a sum assured between 10-40 times the annualised premium...

Am you Required to E-file Tax Return?

Download Tax Saving Mutual Fund Application Forms Invest In Tax Saving Mutual Funds Online Buy Gold Mutual Funds Leave a missed Call on 94 8300 8300   Am I Required to 'E-file' My Return? Yes, under the law you are required to e-file your return if your income for the year is Rs. 500,000 or more. Even if you are not required to e-file your return, it is advisable to do so for the following benefits: i) E-filing is environment friendly. ii) E-filing ensures certain validations before the return is filed. Therefore, e-returns are more accurate than the paper returns. iii) E-returns are processed faster than the paper returns. iv) E-filing can be done from the comfort of home/office and you do not have to stand in queue to e-file. v) E-returns can be accessed anytime from the tax department's e-filing portal. For further information contact Prajna Capit...

IDFC - Long term infrastructure bonds - Tranche 2

IDFC - Long term infrastructure bonds What are infrastructure bonds? In 2010, the government introduced a new section 80CCF under the Income Tax Act, 1961 (" Income Tax Act ") to provide for income tax deductions for subscription to long-term infrastructure bonds and pursuant to that the Central Board of Direct Taxes passed Notification No. 48/2010/F.No.149/84/2010-SO(TPL) dated July 9, 2010. These long term infrastructure bonds offer an additional window of tax deduction of investments up to Rs. 20,000 for the financial year 2010-11. This deduction is over and above the Rs 1 lakh deduction available under sections 80C, 80CCC and 80CCD read with section 80CCE of the Income Tax Act. Infrastructure bonds help in intermediating the retail investor's savings into infrastructure sector directly. Long term infrastructure Bonds by IDFC IDFC issued an earlier tranche of these long term infrastructure bonds on November 12, 2010. This is the second public issue of long-te...

Section 80CCD

Top SIP Funds Online   Income tax deduction under section 80CCD Under Income Tax, TaxPayers have the benefit of claiming several deductions. Out of the deduction avenues, Section 80CCD provides t axpayer deductions against investments made in specific sector s. Under Section 80CCD, an assessee is eligible to claim deductions against the contributions made to the National Pension Scheme or Atal Pension Yojana. Contributions made by an employer to National Pension Scheme are also eligible for deductions under the provisions of Section 80 CCD. In this article, we will take a look at the primary features of this section, the terms and conditions for claiming deductions, the eligibility to claim such deductions, and some of the commonly asked questions in this regard. There are two parts of Section 80CCD. Subsection 1 of this section refers to tax deductions for all assesses who are central government or state government employees, or self-employed or employed by any other employers. In...

Merger of Tata Indo-Global Infrastructure Fund with Tata Equity Opportunities Fund

Download Tax Saving Mutual Fund Application Forms Invest In Tax Saving Mutual Funds Online Buy Gold Mutual Funds Leave a missed Call on 94 8300 8300 Merger of Tata Indo-Global Infrastructure Fund with Tata Equity Opportunities Fund Tata Mutual Fund has decided to merge Tata Indo-Global Infrastructure Fund with Tata Equity Opportunities Fund, with effect from January 16, 2015.   Investors of Tata Indo-Global Infrastructure Fund can redeem/ switch out units from December 13, 2014 to January 12, 2015 without paying any exit load. For further information contact Prajna Capital on 94 8300 8300 by leaving a missed call Leave a missed Call on 94 8300 8300 Leave your comment with mail ID and we will answer them OR You can write back to us at PrajnaCapital [at] Gmail [dot] Com --------------------------------------------- Invest Mutual Funds Online Invest Any Mutual Fund Online Download Mutual Fund Application Forms from all AMCs Download Mutual Any Fund A...
Related Posts Plugin for WordPress, Blogger...
Invest in Tax Saving Mutual Funds Download Any Applications
Transact Mutual Funds Online Invest Online
Buy Gold Mutual Funds Invest Now